520 related articles for article (PubMed ID: 36787659)
1. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
[TBL] [Abstract][Full Text] [Related]
2. Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy.
He Q; Zhou L; Yu D; Zhu R; Chen Y; Song M; Liu X; Liao Y; Ding T; Fan W; Yu W
J Med Chem; 2023 Aug; 66(15):10458-10472. PubMed ID: 37279091
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors.
Yang C; Yang Y; Li Y; Ni Q; Li J
J Am Chem Soc; 2023 Jan; 145(1):385-391. PubMed ID: 36542856
[TBL] [Abstract][Full Text] [Related]
4. Glutathione-Scavenging Nanoparticle-Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects.
Liu HJ; Chen W; Wu G; Zhou J; Liu C; Tang Z; Huang X; Gao J; Xiao Y; Kong N; Joshi N; Cao Y; Abdi R; Tao W
Adv Sci (Weinh); 2023 Jun; 10(16):e2207439. PubMed ID: 37066758
[TBL] [Abstract][Full Text] [Related]
5. Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors.
Fan H; Zhou Z; Yu D; Sun J; Wang L; Jia Y; Tian J; Mi W; Sun H
Bioorg Chem; 2023 Nov; 140():106793. PubMed ID: 37683536
[TBL] [Abstract][Full Text] [Related]
6. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands.
Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968
[TBL] [Abstract][Full Text] [Related]
7. Hydrogen Peroxide-Inducible PROTACs for Targeted Protein Degradation in Cancer Cells.
Yu D; Fan H; Zhou Z; Zhang Y; Sun J; Wang L; Jia Y; Tian J; Campbell A; Mi W; Sun H
Chembiochem; 2023 Sep; 24(17):e202300422. PubMed ID: 37462478
[TBL] [Abstract][Full Text] [Related]
8. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.
He S; Fang Y; Wu M; Zhang P; Gao F; Hu H; Sheng C; Dong G
J Med Chem; 2023 Dec; 66(24):16828-16842. PubMed ID: 38055861
[TBL] [Abstract][Full Text] [Related]
10. Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy.
Gao J; Hou B; Zhu Q; Yang L; Jiang X; Zou Z; Li X; Xu T; Zheng M; Chen YH; Xu Z; Xu H; Yu H
Nat Commun; 2022 Jul; 13(1):4318. PubMed ID: 35882867
[TBL] [Abstract][Full Text] [Related]
11. Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation.
Bi T; Liang P; Zhou Y; Wang H; Huang R; Sun Q; Shen H; Yang S; Ren W; Liu Z
J Med Chem; 2023 Nov; 66(21):14843-14852. PubMed ID: 37871321
[TBL] [Abstract][Full Text] [Related]
12. A platform for the rapid synthesis of proteolysis targeting chimeras (Rapid-TAC) under miniaturized conditions.
Guo L; Zhou Y; Nie X; Zhang Z; Zhang Z; Li C; Wang T; Tang W
Eur J Med Chem; 2022 Jun; 236():114317. PubMed ID: 35397401
[TBL] [Abstract][Full Text] [Related]
13. Radiation responsive PROTAC nanoparticles for tumor-specific proteolysis enhanced radiotherapy.
Xu M; Yun Y; Li C; Ruan Y; Muraoka O; Xie W; Sun X
J Mater Chem B; 2024 Mar; 12(13):3240-3248. PubMed ID: 38437473
[TBL] [Abstract][Full Text] [Related]
14. Photo-regulated PROTACs: A novel tool for temporal control of targeted protein degradation.
Xu H; Ohoka N; Inoue T; Yokoo H; Demizu Y
Bioorg Med Chem Lett; 2024 Jul; 107():129778. PubMed ID: 38702019
[TBL] [Abstract][Full Text] [Related]
15. Nano Proteolysis Targeting Chimeras (PROTACs) with Anti-Hook Effect for Tumor Therapy.
Zhang NY; Hou DY; Hu XJ; Liang JX; Wang MD; Song ZZ; Yi L; Wang ZJ; An HW; Xu W; Wang H
Angew Chem Int Ed Engl; 2023 Sep; 62(37):e202308049. PubMed ID: 37486792
[TBL] [Abstract][Full Text] [Related]
16. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
[TBL] [Abstract][Full Text] [Related]
17. Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022.
Tamatam R; Shin D
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982263
[TBL] [Abstract][Full Text] [Related]
18. PROTACs: Promising approach for anticancer therapy.
Kaur SD; Bedi N; Kumar D; Kapoor DN
Cancer Lett; 2023 Mar; 556():216065. PubMed ID: 36642326
[TBL] [Abstract][Full Text] [Related]
19. Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy.
Zou ZF; Yang L; Nie HJ; Gao J; Lei SM; Lai Y; Zhang F; Wagner E; Yu HJ; Chen XH; Xu ZA
Acta Pharmacol Sin; 2024 Apr; ():. PubMed ID: 38609561
[TBL] [Abstract][Full Text] [Related]
20. Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer.
Minko T
Trends Pharmacol Sci; 2020 Oct; 41(10):684-686. PubMed ID: 32893006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
